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1. INTRODUCTION {#cam43208-sec-0005}
===============

Patients with advanced gastric cancers often develop recurrences, even if the patients undergo curative resections with D2 lymph node dissection.[^1^](#cam43208-bib-0001){ref-type="ref"} Gastric cancer has three predominant recurrence patterns: peritoneal dissemination, hematogenous, and lymph nodal.[^2^](#cam43208-bib-0002){ref-type="ref"} Different clinicopathological signatures reportedly include prognosis and treatment response.[^3^](#cam43208-bib-0003){ref-type="ref"}, [^4^](#cam43208-bib-0004){ref-type="ref"}, [^5^](#cam43208-bib-0005){ref-type="ref"}, [^6^](#cam43208-bib-0006){ref-type="ref"}, [^7^](#cam43208-bib-0007){ref-type="ref"} In the old days, when surgery alone was the standard treatment for advanced gastric cancer, peritoneal recurrence was the most common recurrence pattern in Japan and resulted in the poorest prognosis.[^1^](#cam43208-bib-0001){ref-type="ref"}

The Adjuvant Chemotherapy Trial of S‐1 for Gastric Cancer (ACTS‐GC) indicated postoperative adjuvant chemotherapy with S‐1 improved prognosis compared with surgery alone for patients with stage II/III gastric cancers.[^8^](#cam43208-bib-0008){ref-type="ref"} Decreased peritoneal recurrence was the main cause of the improved prognosis. Few data are available on prognosis after peritoneal, hematogenous, and nodal recurrences after standardization of adjuvant S‐1 treatment. Although several investigators have tried to analyze correlations between initial recurrence sites and prognosis, they have been limited by a small study cohort from a single institution and a long period of data acquisition, accompanied by large changes in disease backgrounds and standard treatment.[^3^](#cam43208-bib-0003){ref-type="ref"}, [^4^](#cam43208-bib-0004){ref-type="ref"}, [^5^](#cam43208-bib-0005){ref-type="ref"}, [^6^](#cam43208-bib-0006){ref-type="ref"}, [^7^](#cam43208-bib-0007){ref-type="ref"}

The objective of our study was to clarify the correlation between initial recurrence site and prognosis after curative resection for gastric cancer using a large‐size multi‐institutional database, acquired between 2010 and 2014.

2. PATIENTS AND METHODS {#cam43208-sec-0006}
=======================

2.1. Patient selection {#cam43208-sec-0007}
----------------------

We retrospectively reviewed the medical records of 3484 patients who underwent gastrectomy for gastric cancer between January 2010 and December 2014, at nine participating institutions. The four eligibility criteria were (a) no preoperative treatment; (b) recurrence after R0 gastrectomy with proper systematic lymphadenectomy performed according to the Japanese Gastric Cancer Treatment Guidelines; (c) pathological stage I/II/III gastric cancer according to the 8th edition of TNM staging system of the Union for International Cancer Control; and (d) sufficient data for analysis. Patients who had initial recurrences at multiple sites, local recurrences, or remnant gastric cancers were excluded from the analysis. Patients were classified into three groups based on their site of recurrence at initial presentation; peritoneal, hematogenous, or nodal recurrence.

This study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki---Ethical Principles for Medical Research Involving Human Subjects. Patients provided written informed consent for surgery and use of clinical data, as required by the Institutional Review Board at each participating institute.

2.2. Surgery and postoperative management {#cam43208-sec-0008}
-----------------------------------------

The patients underwent gastrectomy with systematic lymphadenectomy according to the Japanese Gastric Cancer Treatment Guideline.[^9^](#cam43208-bib-0009){ref-type="ref"} Each patient received postoperative follow‐up that included physical examinations, laboratory tests including serum tumor markers, and enhanced computed tomography (chest and abdominal cavity) once every 6 months for 5 years or until recurrence. S‐1 monotherapy for 12 months or capecitabine plus oxaliplatin for 6 months was recommended for patients with Stage II/III disease (except T1 and T3N0) as postoperative adjuvant treatment unless contraindicated by the patient\'s condition or by patient refusal. Treatment after recurrence was determined according to evidence available at the time, patient\'s condition, and patient\'s consent.

2.3. Statistical analysis {#cam43208-sec-0009}
-------------------------

Data were analyzed using JMP ver14 software (JMP, SAS Institute). Correlations between each group and clinicopathological variables were analyzed by chi‐square test and Fisher\'s exact test for categorical variables, and the Mann‐Whitney *U* test for continuous variables. Survival data were calculated using the Kaplan‐Meier method; differences in survival were examined with the Wilcoxon signed‐rank test. *P* \< .05 was considered significant.

3. RESULTS {#cam43208-sec-0010}
==========

3.1. Clinicopathologic characteristics and treatment {#cam43208-sec-0011}
----------------------------------------------------

A study flow‐chart is presented in Figure [1](#cam43208-fig-0001){ref-type="fig"}. Among the 365 patients who developed recurrences, we excluded 52 patients who had multiple site recurrences (n = 33), local recurrences (n = 14), or recurrences at the remnant stomach (n = 5). The remaining 313 patients were classified as having peritoneal (n = 127), hematogenous (n = 123), or nodal recurrences (n = 63). Their characteristics are summarized in Table [1](#cam43208-tbl-0001){ref-type="table"}. Patients' pathological stages were stage I: n = 20 (6%), II: n = 62 (20%), and III: n = 231 (74%). Postoperative adjuvant chemotherapy was administrated to 190 (63%) patients. We compared clinical characteristics between patients who underwent adjuvant chemotherapy and who did not. Patients who did not receive adjuvant chemotherapy had earlier stage, older age, and higher comorbidity rates (Table [S1](#cam43208-sup-0002){ref-type="supplementary-material"}).

![Flow diagram for study participants](CAM4-9-5392-g001){#cam43208-fig-0001}

###### 

Patient characteristics

  Variables               n = 313
  ----------------------- -------------
  Age                     
  Mean ± SD               70.0 ± 9.89
  Sex                     
  Male                    220 (70%)
  Female                  93 (30%)
  Method of resection     
  Total gastrectomy       153 (49%)
  Others                  160 (51%)
  Tumor location          
  Entire                  23 (7%)
  Upper third             88 (28%)
  Middle third            83 (27%)
  Lower third             111 (35%)
  Remnant                 8 (3%)
  Macroscopic type        
  Borrmann type 4         35 (11%)
  Others                  278 (89%)
  Differentiation         
  Differentiated          134 (43%)
  Undifferentiated        176 (57%)
  pT                      
  1                       24 (8%)
  2                       22 (7%)
  3                       94 (30%)
  4                       173 (55%)
  pN                      
  0                       49 (16%)
  1                       46 (15%)
  2                       83 (26%)
  3                       135 (43%)
  pStage (UICC 8th)       
  Ⅰ                       20 (6%)
  Ⅱ                       62 (20%)
  Ⅲ                       231 (74%)
  Adjuvant chemotherapy   
  Absent                  111 (37%)
  Present                 190 (63%)

Abbreviations: SD, standard deviation;UICC, Union for international Cancer Control.
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Patients' clinicopathologic factors by peritoneal, hematogenous, and nodal recurrence groups are presented in Table [2](#cam43208-tbl-0002){ref-type="table"}. Patients in the peritoneal group had a significantly greater percentage of younger patients, macroscopic Borrmann type 4, undifferentiated type, invasive growth type, and advanced pT stage. Patients in the hematogenous group had a significantly greater percentage of smaller tumors than the other two groups. The predominant recurrence sites among patients with pT4 tumors were peritoneal (60.1%, 104/173). Clinical characteristics of pStage I patients with postoperative recurrences were summarized in Table [S2](#cam43208-sup-0003){ref-type="supplementary-material"}. Additionally, when focusing on patients with pT1 tumors, the predominant recurrence sites were hematogenous (62.5%, 15/24), followed by nodal (37.5%, 9/24) and no patients with pT1 tumors had peritoneal recurrence.

###### 

Comparison of patient characteristics with peritoneal recurrence (P‐rec), hematogenous recurrence (H‐rec), and nodal recurrence (N‐rec)

+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Variables                | P‐rec       | H‐rec       | N‐rec       | *P*‐value |        |        |
|                          |             |             |             |           |        |        |
|                          | n = 127     | n = 123     | n = 63      |           |        |        |
+==========================+=============+=============+=============+===========+========+========+
| Age                      |             |             |             | \<.001    | .962   | .007   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Mean ± SD                | 67.6 ± 11.0 | 71.7 ± 8.86 | 71.6 ± 8.58 |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Sex                      |             |             |             | \<.001    | .098   | .074   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Male                     | 74 (58%)    | 101 (82%)   | 45 (71%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Female                   | 53 (42%)    | 22 (18%)    | 18 (29%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| CEA                      |             |             |             | .014      | .170   | .552   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| ≤5                       | 98 (80%)    | 72 (66%)    | 42 (76%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| \>5                      | 24 (20%)    | 37 (34%)    | 13 (24%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| CA19‐9                   |             |             |             | .118      | .735   | .358   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| ≤37                      | 98 (80%)    | 78 (72%)    | 40 (74%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| \>37                     | 24 (20%)    | 31 (28%)    | 14 (26%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Method of resection      |             |             |             | .316      | .111   | .016   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Total gastrectomy        | 70 (55%)    | 60 (49%)    | 23 (37%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Others                   | 57 (45%)    | 63 (51%)    | 40 (63%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Tumor location           |             |             |             | .015      | .002   | .002   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Entire                   | 17 (13%)    | 6 (5%)      | 0 (0%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Upper third              | 29 (23%)    | 46 (38%)    | 13 (20%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Middle third             | 33 (26%)    | 35 (28%)    | 15 (24%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Lower third              | 44 (35%)    | 35 (28%)    | 32 (51%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Remnant                  | 4 (3%)      | 1 (1%)      | 3 (5%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Tumor size               |             |             |             | .005      | .016   | .887   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| \<50                     | 44 (35%)    | 64 (52%)    | 21 (34%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| ≥50                      | 82 (65%)    | 58 (48%)    | 41 (66%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Macroscopic type         |             |             |             | .002      | .34    | .002   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Borrmann type 4          | 25 (20%)    | 8 (7%)      | 2 (3%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Others                   | 102 (80%)   | 115 (93%)   | 61 (97%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Differentiation          |             |             |             | \<.001    | .019   | .006   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Differentiated           | 31 (24%)    | 75 (63%)    | 28 (44%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Undifferentiated         | 96 (76%)    | 45 (37%)    | 35 (56%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Lymphatic involvement    |             |             |             | .031      | .033   | .638   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Absent                   | 6 (5%)      | 15 (12%)    | 2 (3%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Present                  | 121 (95%)   | 108 (88%)   | 59 (97%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Vessel invasion          |             |             |             | .885      | .881   | .788   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Absent                   | 31 (24%)    | 31 (25%)    | 16 (26%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Present                  | 96 (76%)    | 92 (75%)    | 45 (74%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Infiltrative growth type |             |             |             | \<.001    | .973   | \<.001 |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Invasive growth          | 87 (70%)    | 29 (24%)    | 14 (24%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Expansive growth         | 38 (30%)    | 90 (76%)    | 44 (76%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| pT                       |             |             |             | \<.001    | .806   | \<.001 |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 1                        | 0 (0%)      | 15 (12%)    | 9 (14%)     |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 2                        | 5 (4%)      | 13 (10%)    | 4 (7%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 3                        | 18 (14%)    | 50 (41%)    | 26 (41%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 4                        | 104 (82%)   | 45 (37%)    | 24 (38%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| pN                       |             |             |             | .002      | \<.001 | .240   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 0                        | 21 (17%)    | 23 (19%)    | 5 (8%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 1                        | 12 (9%)     | 28 (22%)    | 6 (9%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 2                        | 32 (25%)    | 38 (31%)    | 13 (21%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| 3                        | 62 (49%)    | 34 (28%)    | 39 (62%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| pStage (UICC 8th)        |             |             |             | \<.001    | .071   | .001   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Ⅰ                        | 0 (0%)      | 14 (11%)    | 6 (9%)      |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Ⅱ                        | 22 (17%)    | 32 (26%)    | 8 (13%)     |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Ⅲ                        | 105 (83%)   | 77 (63%)    | 49 (78%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Adjuvant chemotherapy    |             |             |             | .002      | .223   | .192   |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Absent                   | 34 (28%)    | 54 (47%)    | 23 (37%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+
| Present                  | 89 (72%)    | 62 (53%)    | 39 (63%)    |           |        |        |
+--------------------------+-------------+-------------+-------------+-----------+--------+--------+

Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; SD, standard deviation; UICC, Union for international Cancer Control.
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3.2. Survival outcomes {#cam43208-sec-0012}
----------------------

Median follow‐up duration for all 313 patients was 23.8 months (range: 1.2‐114.3 months). Their median disease‐specific survival was 27.8 months (95% CI: 23.8‐31.8). The peritoneal, hematogenous, and nodal recurrence groups did not significantly differ in disease‐specific survival (25.8 vs 29.0 vs 27.8 months; peritoneal vs hematogenous, *P* = .152; hematogenous vs nodal, *P* = .955; peritoneal vs nodal, *P* = .213; Figure [2](#cam43208-fig-0002){ref-type="fig"}). Moreover, the subgroup analysis according to adjuvant chemotherapy indicated that disease‐specific survival times after surgery were similar among patients with peritoneal, hematogenous, or nodal recurrences in both subgroups (with and without adjuvant chemotherapy) (Figure [S1](#cam43208-sup-0001){ref-type="supplementary-material"}).

![Disease‐specific survival for peritoneal recurrence (P‐rec), hematogenous recurrence (H‐rec), and nodal recurrence (N‐rec) groups. \**P* \< .05](CAM4-9-5392-g002){#cam43208-fig-0002}

Median recurrence‐free survival time was 12.2 months (95% CI: 11.2‐14.1). However, recurrence‐free survival in the peritoneal recurrence group was significantly longer than in the hematogenous recurrence group (15.2 vs 10.7 vs 12.2 months; peritoneal vs hematogenous, *P* = .001; hematogenous vs nodal, *P* = .172; peritoneal vs nodal, *P* = .111; Figure [3A](#cam43208-fig-0003){ref-type="fig"}). Median post‐recurrence survival was 10.9 months (95% CI: 9.0‐13.5). Post‐recurrence survival in the hematogenous and nodal recurrence groups did not significantly differ (15.0 vs 15.2 months; *P* = .959), but it was significantly shorter for the peritoneal recurrence group (7.6 months; peritoneal vs hematogenous, *P* \< .001; peritoneal vs nodal, *P* = .007; Figure [3B](#cam43208-fig-0003){ref-type="fig"}).

![Recurrence‐free survival (A) and post‐recurrence survival (B) for peritoneal recurrence (P‐rec), hematogenous recurrence (H‐rec), and nodal recurrence (N‐rec) groups. \**P* \< .05](CAM4-9-5392-g003){#cam43208-fig-0003}

4. DISCUSSION {#cam43208-sec-0013}
=============

In this study, we demonstrated that disease‐specific survival after curative resection of gastric cancer was similar among patients with peritoneal, hematogenous, or nodal recurrences, using a multi‐institutional dataset from patients who underwent gastrectomy after postoperative adjuvant S‐1 became the standard treatment.

Peritoneal metastasis has long been the predominant type of recurrence in the Asia, and it is associated with dismal prognosis because of lack of an effective treatment.[^1^](#cam43208-bib-0001){ref-type="ref"} In the last decade, early detection of gastric cancer by health screening systems and standardization of adjuvant treatment have reduced risk of peritoneal recurrence and improved prognosis.[^8^](#cam43208-bib-0008){ref-type="ref"}, [^10^](#cam43208-bib-0010){ref-type="ref"}, [^11^](#cam43208-bib-0011){ref-type="ref"}, [^12^](#cam43208-bib-0012){ref-type="ref"} However, percentages of hematogenous and nodal recurrences increased with changes in characteristics of Asian gastric cancer, particularly by eradication of *Helicobacter pylori*, and reduction of peritoneal recurrences by S‐1 adjuvant.[^13^](#cam43208-bib-0013){ref-type="ref"}, [^14^](#cam43208-bib-0014){ref-type="ref"}

In this study, we compared prognosis (disease‐specific, recurrence‐free, and post‐recurrence survival) among patients with peritoneal, hematogenous, or nodal recurrences. Disease‐specific survival times were similar between the three groups, however, recurrence‐free survival in the peritoneal recurrence group was longer than in the hematogenous recurrence group. Additionally, post‐recurrence survival of patients with peritoneal recurrence was shorter than those with hematogenous or lymph nodal recurrence. The longer recurrence‐free survival, but shorter post‐recurrence survival, in the peritoneal recurrence group is interesting. One speculation is that S‐1 adjuvant delays the onset of peritoneal recurrence, but the recurrent disease is more refractory to chemo‐ and radiotherapy and thus associated with shortened survival.[^15^](#cam43208-bib-0015){ref-type="ref"} Another is that peritoneal recurrences are diagnosed at later stages with a larger tumor burden because of difficulty in early detection by imaging modalities. Diagnostic methods of disease recurrences had not been prescribed for this study. Because staging laparoscopy is an invasive procedure requiring general anesthesia, it is unrealistic to use it for routine postoperative surveillance. Most of peritoneal recurrences were detected by computed tomography. The sensitivity of computed tomography or fluorodeoxyglucose positron emission tomography for detecting small peritoneal metastasis is low.[^16^](#cam43208-bib-0016){ref-type="ref"} Development of more sensitive markers that can enhance the opportunity to detect peritoneal recurrences before appearance of overt ascites fluids or peritoneal nodules could improve this situation.[^17^](#cam43208-bib-0017){ref-type="ref"}, [^18^](#cam43208-bib-0018){ref-type="ref"}, [^19^](#cam43208-bib-0019){ref-type="ref"}, [^20^](#cam43208-bib-0020){ref-type="ref"}

It is difficult to directly translate our findings into clinical practice. However, data on prognosis after recurrences enable physicians to provide adequate informed consent information to patients having a postoperative recurrence of gastric cancer. Moreover, it is helpful for physicians to estimate postoperative periods that need to be paid special caution for each recurrent pattern and might improve a quality of postoperative surveillance programs.

Some previous reports described relationships between sites of initial recurrence and the clinicopathological characteristics.[^3^](#cam43208-bib-0003){ref-type="ref"}, [^6^](#cam43208-bib-0006){ref-type="ref"}, [^7^](#cam43208-bib-0007){ref-type="ref"} For example, Lee et al reported that patterns of recurrence vary significantly based on Lauren histologic type. They showed that the most common site for intestinal tumors was distant metastasis (54%) and the most common site for diffuse/mixed tumors, was peritoneal recurrence (37%).[^6^](#cam43208-bib-0006){ref-type="ref"} Our data indicate that peritoneal recurrence was associated with macroscopic Borrmann type 4, undifferentiated type, invasive growth type, and advanced pT stage. Treatment and surveillance strategies could be tailored to clarify differences in risk factors among recurrence sites.

Takahashi et al reported timing and site‐specific trends of recurrence in a Japanese high‐volume center.[^21^](#cam43208-bib-0021){ref-type="ref"} We found that the administration rate of adjuvant chemotherapy was only 64% in those patients probably because of multi‐institutional dataset including elderly patients having comorbidities from regional hospitals. Patients who did not receive adjuvant chemotherapy had earlier stage, older age, and higher comorbidity rates. Moreover, the subgroup analysis according to adjuvant chemotherapy indicated that disease‐specific survival times after surgery were similar among patients with peritoneal, hematogenous, or nodal recurrences in both subgroups (with and without adjuvant chemotherapy). These findings are unique points from a previous study reported by Takahashi et al.[^21^](#cam43208-bib-0021){ref-type="ref"}

Some limitations associated with this study should be mentioned. First, this is a retrospective analysis. Second, only 63 patients had nodal recurrences. Third, information on treatment after recurrences is insufficient. Fourth, we have no data on disease symptoms or detection methods for the diagnoses of these recurrences.

Taken together, our multi‐institutional dataset analysis revealed that prognosis was similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resection of gastric cancer.
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